Recently, CLEC1B was confirmed to be remarkably downregulated and related to tumor hemorrhage in HCC, indicating that CLEC1B could be served as a potential target for PD-L1/PD1 immunotherapy [28, 42]. This evidence concerns the gene CLEC1B and hepatocellular carcinoma.